Rasio cepet REGENXBIO Inc. (RGNX)

REGENXBIO Inc. (RGNX) demonstrates independence from market volatility, as its growth is driven by successful trials and patents. The company has developed a core gene delivery system that serves as the foundation for treating blindness and atrophy. The asset value tracked on this chart is currently 2.80. Long-term stability is secured by multi-year contracts with industry behemoths, guaranteeing regular payments for the use of intellectual property.

The quick ratio is calculated by dividing the sum of cash and accounts receivable by current liabilities. This metric assesses a business's ability to settle debts instantaneously, completely excluding illiquid inventory from the calculation. For REGENXBIO Inc. (RGNX), such a financial cushion is critical, as the stability of a biotechnology business depends on the pace of clinical trials rather than market cycles. The trend of this strict liability coverage ratio reflects the company's actual margin of safety during periods of new drug development.